Eris Lifesciences Limited IPO
Eris Lifesciences Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹600–₹603 per share to raise ₹1,741 crore. The issue was subscribed 3.29× overall (QIBs 4.68×, NIIs 0.45×, retail 3.51×). It listed on 29 Jun 2017 at ₹611 and closed its first day at ₹602, a listing loss of -0.2% versus the ₹603 issue price. It now trades around ₹1,156 (+91.8% versus the issue price).
Frequently asked questions
- How many times was the Eris Lifesciences Limited IPO subscribed?
- The Eris Lifesciences Limited IPO was subscribed 3.29× overall — 4.68× in the QIB category, 0.45× among non-institutional investors, 3.51× in retail.
- What were the Eris Lifesciences Limited IPO listing gains?
- Eris Lifesciences Limited listed on 29 Jun 2017 at ₹611, closing its first day at ₹602 — a listing loss of -0.2% versus the ₹603 issue price.
- What were the retail allotment odds for the Eris Lifesciences Limited IPO?
- Retail was subscribed 3.51×, so a single-lot application had roughly a 28.5% chance of allotment (about 1 in 4), and allotment was finalised on 23 Jun 2017.
- What was the price band and lot size of the Eris Lifesciences Limited IPO?
- The price band was ₹600–₹603 per share, with a minimum lot of 24 shares (₹14,472 at the upper band).
- Who were the registrar and lead manager for the Eris Lifesciences Limited IPO?
- Link Intime India Private Limited was the registrar, and Axis Capital was the book-running lead manager.